Compare KeyCorp (KEY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Smith & Nephew plc — how do they compare? KeyCorp trades at $19.97 (market cap $21.45B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: KeyCorp is the larger of the two by market cap, and KeyCorp pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and Smith & Nephew plc for 121 Days on average.
| KEY | SNN | |
|---|---|---|
Market Cap | $21.45B | $11.10B |
Volume | 19,450,846 | 1,051,703 |
Sector | Financials | Health |
52-Week High | $23.99 | $37.17 |
52-Week Low | $16.78 | $26.42 |
Typical Hold Time | 66 Days | 121 Days |
Enterprise Value | $34.63B | $14.13B |
Dividend Yield | 4.08% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $20.10, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments in wealth and retail banking.
The outlook is supported by analyst consensus with a $25.00 price target and 60.79% buy ratings, though risks include volatile cash flows and competitive pressures. Revenue growth momentum and aggressive share buybacks provide upside potential, but investors should weigh the frozen dividend against peers and monitor interest rate impacts on net interest income.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
